CD19 and B-cell non-Hodgkin lymphoma: In the domain of CAR-T cell therapies, Breyanzi (lisocabtagene maraleucel), approved in 2021, introduced a new generation of CAR-T therapies targeting CD19 for large B-cell lymphoma, offering enhanced efficacy and safety profiles compared to earlier products.524–544 Additionally, Abecma (idecabtagene vicleucel) was approved in 2021 as the first CAR-T cell therapy for relapsed or refractory multiple myeloma, addressing unmet needs in hematologic malignancies.545–563